

Fiscal Year 2010 Annual Review of Symlin®
 Oklahoma HealthCare Authority
 April 2011

Prior Authorization Criteria

Members with type 1 and 2 diabetes using insulin must:

1. be using a basal-bolus insulin regimen (basal insulin plus rapid acting with meals);
2. have failed to achieve adequate glycemic control (on basal-bolus regimen) or are gaining excessive weight (on basal-bolus regimen); and
3. receiving ongoing care under the guidance of a health care professional.

Members meeting the following criteria should NOT be considered for Symlin® therapy:

1. Poor compliance with insulin regimen
2. Poor compliance with self-blood glucose monitoring
3. HbA1c > 9%
4. Recurrent severe hypoglycemia requiring assistance in past 6 months
5. Presence of hypoglycemia unawareness
6. Diagnosis of gastroparesis
7. Require use of drugs that stimulate GI motility
8. Pediatric patients (≤ 15 years old)

Utilization of Symlin®

Comparison of Fiscal Years


Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2009	4	15	\$6,402.97	\$426.86	\$15.21	211	421
2010	9	31	\$18,138.77	\$585.12	\$20.57	427	882
% Change	125.0%	106.7%	183.3%	37.1%	35.2%	102.4%	109.5%
Change	5	16	\$11,735.80	\$158.26	\$5.36	216	461

Utilization Details

Medication	Claims	Members	Units	Days	Cost	Units/Day	% Cost
SYMLIN INJ 600MCG	14	2	260	405	\$9,539.64	0.64	52.59%
SYMLNPEN 120 INJ 1000MCG	14	5	160	420	\$8,195.84	0.38	45.18%
SYMLINPEN 60 INJ 1000MCG	3	2	8	57	\$403.29	0.13	2.2%
TOTALS	100,795	9*	428	882	\$18,138.77	0.49	100%

*Total number of unduplicated members

Demographics of Members Utilizing Symlin®: FY 2010



Prescribers of Symlin® by Number of Claims: FY 2010

Specialty	Claims
Internist	17
Family Practitioner	12
Nurse Practitioner (Other)	2

Prior Authorization of Symlin®

There were a total of 31 petitions submitted for Symlin® during fiscal year 2010. The following chart shows the status of the submitted petitions.

Status of Petitions for Antidepressant Medications: FY 2009

Status	Total PA Count
Approved	11
Denied	18
Incomplete	2

Conclusion and Recommendations

The College of Pharmacy recommends continuing the current criteria for Symlin®.